Alexion Pharmaceuticals (ALXN) Holder University Of Notre Dame Du Lac Has Decreased Holding by $406,840; As Regis Minn (RGS) Stock Value Declined, Holder North Run Capital LP Has Lifted Holding

January 16, 2018 - By Vivian Park

Thomas Ellis increased its stake in Regis Corp Minn (RGS) by 454.15% based on its latest 2017Q3 regulatory filing with the SEC. North Run Capital Lp bought 960,353 shares as the company’s stock declined 24.96% while stock markets rallied. The hedge fund run by Thomas Ellis held 1.17 million shares of the other consumer services company at the end of 2017Q3, valued at $16.72 million, up from 211,462 at the end of the previous reported quarter. North Run Capital Lp who had been investing in Regis Corp Minn for a number of months, seems to be bullish on the $717.78M market cap company. The stock increased 0.26% or $0.04 during the last trading session, reaching $15.41. About 4,600 shares traded. Regis Corporation (NYSE:RGS) has declined 23.62% since January 16, 2017 and is downtrending. It has underperformed by 40.32% the S&P500.

University Of Notre Dame Du Lac decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 7.12% based on its latest 2017Q3 regulatory filing with the SEC. University Of Notre Dame Du Lac sold 2,906 shares as the company’s stock declined 11.63% while stock markets rallied. The institutional investor held 37,926 shares of the health care company at the end of 2017Q3, valued at $5.32M, down from 40,832 at the end of the previous reported quarter. University Of Notre Dame Du Lac who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $28.09B market cap company. The stock increased 2.46% or $3.02 during the last trading session, reaching $125.73. About 328,728 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since January 16, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Investors sentiment decreased to 1.02 in Q3 2017. Its down 0.14, from 1.16 in 2017Q2. It fall, as 7 investors sold RGS shares while 43 reduced holdings. 18 funds opened positions while 33 raised stakes. 44.07 million shares or 0.73% more from 43.75 million shares in 2017Q2 were reported. State Of Tennessee Treasury Department invested 0% of its portfolio in Regis Corporation (NYSE:RGS). Barclays Public Limited Com stated it has 0% of its portfolio in Regis Corporation (NYSE:RGS). Oaktree Capital Management Lp accumulated 321,890 shares. Tower Rech Cap Lc (Trc) owns 2,254 shares. The Maryland-based Price T Rowe Associate Md has invested 0% in Regis Corporation (NYSE:RGS). Moreover, Renaissance Tech has 0.04% invested in Regis Corporation (NYSE:RGS) for 2.13 million shares. Employees Retirement Association Of Colorado invested 0% of its portfolio in Regis Corporation (NYSE:RGS). Legal And General Gru Public Limited Com has 0% invested in Regis Corporation (NYSE:RGS). 13,615 were reported by Appleton Prns Incorporated Ma. Mason Street Advisors Lc accumulated 8,815 shares. Arizona State Retirement Systems holds 18,057 shares or 0% of its portfolio. Ameriprise Fin Inc accumulated 243,420 shares. Jpmorgan Chase holds 1.34M shares or 0% of its portfolio. State Board Of Administration Of Florida Retirement System stated it has 0% in Regis Corporation (NYSE:RGS). Arrowmark Colorado Hldgs Limited Liability Corporation invested in 0.05% or 285,601 shares.

Among 4 analysts covering Regis Corporation (NYSE:RGS), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Regis Corporation had 7 analyst reports since August 31, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Thursday, November 19 by Piper Jaffray. The firm has “Sell” rating given on Monday, August 31 by Northcoast. The stock of Regis Corporation (NYSE:RGS) has “Buy” rating given on Wednesday, November 1 by Jefferies. The stock of Regis Corporation (NYSE:RGS) earned “Neutral” rating by Northcoast on Friday, October 30. The firm has “Hold” rating given on Wednesday, December 20 by KeyBanc Capital Markets. Piper Jaffray downgraded the shares of RGS in report on Thursday, May 19 to “Underweight” rating.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It worsened, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. 3 were reported by Ent. Thomas J Herzfeld Advsr has 88 shares for 0.01% of their portfolio. Raymond James Na owns 2,132 shares or 0.02% of their US portfolio. Moreover, First Republic Management Incorporated has 0% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 2,040 were reported by Rathbone Brothers Plc. Td Asset Inc has invested 0.09% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Lazard Asset Ltd Liability Com has 12 shares for 0% of their portfolio. Edgewood Ltd Company reported 5,094 shares stake. 1.41M are owned by Dsm Capital Prtn Limited Liability. Sequent Asset Management Limited Liability holds 0.41% or 5,000 shares in its portfolio. Lockheed Martin Investment Mngmt reported 0.06% stake. Aperio Gru Lc reported 71,628 shares stake. Tourbillon Capital Prns Ltd Partnership accumulated 1.58M shares or 5.35% of the stock. Invest Mgmt Of Virginia Ltd has invested 0.16% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Bp Public Limited Co stated it has 26,000 shares.

Among 28 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 23 have Buy rating, 0 Sell and 5 Hold. Therefore 82% are positive. Alexion Pharmaceuticals Inc. had 89 analyst reports since July 27, 2015 according to SRatingsIntel. Jefferies maintained it with “Hold” rating and $12000 target in Wednesday, June 7 report. The firm has “Buy” rating by Leerink Swann given on Monday, September 25. The stock has “Overweight” rating by Barclays Capital on Tuesday, November 29. The firm has “Overweight” rating by PiperJaffray given on Monday, October 23. The rating was initiated by BMO Capital Markets with “Market Perform” on Thursday, April 7. Barclays Capital maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, July 29 with “Equal-Weight” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, September 12 report. The company was maintained on Thursday, February 4 by UBS. The firm has “Outperform” rating by BMO Capital Markets given on Friday, July 28. On Friday, October 2 the stock rating was upgraded by Morgan Stanley to “Overweight”.

Since July 31, 2017, it had 0 buys, and 6 selling transactions for $2.74 million activity. The insider HANTSON LUDWIG sold 2,553 shares worth $310,521. Wagner Heidi L also sold $16,800 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. $1.56M worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by O’Neill Julie.

University Of Notre Dame Du Lac, which manages about $359.00M US Long portfolio, upped its stake in Seattle Genetics Inc (NASDAQ:SGEN) by 16,024 shares to 55,319 shares, valued at $3.01 million in 2017Q3, according to the filing. It also increased its holding in Biomarin Pharmaceutical Inc (NASDAQ:BMRN) by 7,120 shares in the quarter, for a total of 61,086 shares, and has risen its stake in Ciena Corp (NYSE:CIEN).

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 15. They expect $1.08 EPS, down 1.82% or $0.02 from last year’s $1.1 per share. ALXN’s profit will be $241.28M for 29.10 P/E if the $1.08 EPS becomes a reality. After $1.28 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -15.63% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts